Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Blood Rev. 2022 Apr 9;55:100950. doi: 10.1016/j.blre.2022.100950

Table 1.

Summary of sphingolipid-targeting agents in preclinical development for AML. Compounds listed were used as anti-neoplastic agents or tool compounds in AML.

Target(s) Sphingolipid Drug References
Ceramide analogs and ceramide inducing compounds
Acid ceramidase LCL-204 [70]
Acid ceramidase SACLAC [82, 151]
Glucosylceramide synthase PDMP [150, 151, 208, 222]
Glucosylceramide synthase PPMP [141, 208]
Mitochondria Pyridinium-ceramide (LCL-461) [92]
Antagonists of S1P synthesis and signaling
Sphingosine kinase 1 Akt A-674563 [107]
Sphingosine kinase 1 SK1-I [106, 151]
Sphingosine kinase 1 & 2 MP-A08 [74]
Sphingosine kinase 1 & 2 SKI-II [200, 222]
Sphingosine kinase 1 & 2 SKI-178 [72, 73]
Sphingosine kinase 1 & 2 SKI-349 [201]
S1PR 2 & 4 DES1 Sphingosine kinase 1 & 2 JTE-013 [74, 108]